ライフサイエンスコーパス: troglitazone

1 cific RXR agonist, or the PPARgamma agonist, troglitazone.

2 tin expression in the absence or presence of troglitazone.

3 nitiation inhibitors such as clotrimazole or troglitazone.

4 xposure to a potent PPARgamma ligand such as troglitazone.

5 fects are achieved with acute treatment with troglitazone.

6 tamate exposure, with or without 15d-PGJ2 or troglitazone.

7 again after 4 days of dexamethasone added to troglitazone.

8 ing adipocytes requires constant exposure to troglitazone.

9 poglycemia during insulin sensitization with troglitazone.

10 diponectin-null animals failed to respond to troglitazone.

11 and 10 micromol/L 15d-PGJ2 and 20 micromol/L troglitazone.

12 metastatic disease were treated orally with troglitazone.

13 ic antigen was seen in patients treated with troglitazone.

14 or C/EBPalpha but not the thiazolidinedione troglitazone.

15 y (ZF) rats, and mouse islets incubated with troglitazone.

16 ctivity, which are reversed by both ACEA and troglitazone.

17 ment of fat cells with the PPARgamma ligand, troglitazone.

18 eveloped through structural modifications of troglitazone.

19 NLS stabilized by the FABP4/PPARgamma ligand troglitazone.

20 ptional repression was independent of T3 and troglitazone.

21 Fifteen pigs were treated with troglitazone (10 mg/kg load, 5 mg. kg(-1). h(-1) infusio

22 ter assays showed that the PPARgamma ligands troglitazone (10(-5) M), pioglitazone (10(-5) M), or 15-

23 hermore, in a pilot study, administration of troglitazone (12 weeks, 600 mg/day), but not placebo, to

24 e phosphorylation of Akt was augmented after troglitazone (170 +/- 34% of pre-Rx response, P < 0.05)

25 P450 2C8 complexed with montelukast (2.8 A), troglitazone (2.7 A), felodipine (2.3 A), and 9-cis-reti

26 ought to ascertain whether pretreatment with troglitazone (20 days) could prevent acute free fatty ac

27 significance (baseline, 33.5 +/- 4.7; after troglitazone, 25.6 +/- 5.2 microg/l).

28 striking inhibition was found at 3200 mg/kg troglitazone (344+/-76 versus 172+/-83 macrophages, P=0.

29 bo (n = 133) or the insulin-sensitizing drug troglitazone (400 mg/day; n = 133) administered in doubl

30 A 7-day treatment with troglitazone (400 mg/kg) significantly reduced monocyte/

31 rapy with either metformin (2,550 mg/day) or troglitazone (600 mg/day) for 3-4 months.

32 ailed glyburide treatment by the addition of troglitazone (600 mg/day) or metformin (2,550 mg/day) th

33 ' treatment with the thiazolidinedione (TZD) troglitazone (600 mg/day).

34 before and after 3 months of treatment with troglitazone (600 mg/day).

35 and at the end of 12 weeks of treatment with troglitazone (600 mg/day, n = 4), metformin ( approximat

36 r of the disease, the oral administration of troglitazone (600-800 mg/day) reduced the increase veloc

37 Juvenile pigs (n=6) were treated with troglitazone (75 mg. kg(-1). d(-1) PO) for 8 weeks.

38 vere bridging and submassive necrosis due to troglitazone (a thiazolidinedione antidiabetic agent).

39 It is interesting that troglitazone (a thiazolidinedione drug) reversed the inh

40 duced insulin resistance and its reversal by troglitazone, a cause-and-effect relationship cannot be

41 Treating the preadipocytes with troglitazone, a potent PPARgamma ligand, could circumven

42 By contrast, troglitazone, a PPARgamma agonist, decreased the levels

43 as demonstrated by the displacement of [(3)H]troglitazone, a PPARgamma agonist, in a scintillation pr

44 Troglitazone, a PPARgamma agonist, strongly suppressed u

45 Troglitazone, a second ACS4 inhibitor, inhibited ACS act

46 one and pioglitazone potentiated cell death, troglitazone acted as a potent cytoprotective agent.

47 Troglitazone activates protein-tyrosine phosphatase (PTP

48 Troglitazone acts as a partial agonist for PPAR-gamma in

49 alpha (nafenopin) and gamma (ciglitazone and troglitazone) agonists rapidly induced extracellular sig

50 ) and synthetic ligands like ciglitazone and troglitazone, all induce apoptosis in normal and maligna

51 dexamethasone (4 mg/day), after 4-6 weeks on troglitazone alone (400 mg/day), and again after 4 days

52 Troglitazone alone increased GDRs by 20% over baseline (

53 ly increased when the cells are induced with troglitazone alone or with a mixture of troglitazone, in

54 ance by troglitazone, but not in response to troglitazone alone.

55 d the metabolic effects of dexamethasone and troglitazone, alone and in combination, for the first ti

56 Exposure of LIP-expressing preadipocytes to troglitazone along with DEX, MIX, and insulin induces di

57 15-d-PGJ2 and troglitazone also blocked NF-kappaB activation by recrui

58 Treatment with troglitazone also disrupted TGF beta 1-activated SAPK/JN

59 Further, troglitazone also induced p53 protein expression in HCT1

60 Troglitazone also inhibited the currents through voltage

61 ivation of PPARgamma by the synthetic ligand troglitazone also reduced tube formation in vitro and in

62 ctal cancer: citalopram (an antidepressant), troglitazone (an antidiabetic), and enilconazole (a fung

63 rmalities in these tissues can be blocked by troglitazone, an inhibitor of FA accumulation.

64 Here we show that PPARgamma ligands, troglitazone and 15-deoxy-Delta(12,14) prostaglandin J(2

65 ted by treatment with the PPAR-gamma ligands troglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2

66 linemic-euglycemic clamps in ZFF showed that troglitazone and AGN194204 reduced basal endogenous gluc

67 We report here that troglitazone and another TZD, ciglitazone, dramatically

68 isome proliferator-activated receptor gamma (troglitazone and BRL46593) and of retinoid X receptor (L

69 Troglitazone and bromfenac are two recently approved med

70 Second, the PPARgamma-inactive analogs of troglitazone and ciglitazone [Delta2TG (5-[4-(6-hydroxy-

71 First, the novel function of troglitazone and ciglitazone in targeting energy restric

72 xy-Delta12,14-prostaglandin J2 (15d-PGJ2) or troglitazone and ciglitazone suppressed TGF-beta1-mediat

73 receptor gamma (PPARgamma) agonists, such as troglitazone and ciglitazone, exhibit antitumor effects;

74 re not reproduced by the PPARgamma agonists, troglitazone and ciglitazone.

75 ects LNCaP cells from apoptosis induction by troglitazone and Delta2-TG in an expression level-depend

76 Nevertheless, it is noteworthy that troglitazone and Delta2TG at high doses were able to inh

77 in immunoprecipitation studies indicate that troglitazone and Delta2TG block AR recruitment to the an

78 Although 10 microM troglitazone and Delta2TG significantly inhibit PSA secr

79 Evidence suggests that troglitazone and derivatives mediate the transcriptional

80 is study investigates the mechanism by which troglitazone and derivatives suppress AR expression in L

81 We demonstrate that troglitazone and its more potent PPARgamma-inactive anal

82 ells are sensitive to apoptosis induction by troglitazone and its PPARgamma-inactive analogue irrespe

83 Troglitazone and other PPARgamma ligands have been shown

84 Troglitazone and pioglitazone differ in their influence

85 We tested the influence of troglitazone and pioglitazone on different parameters of

86 s (15-deoxy-Delta(12,14)-prostaglandin J(2), troglitazone and pioglitazone) suppressed the growth of

87 these genes can be selectively modulated by troglitazone and represent potential novel targets for c

88 ausing cancer cell death than the activators troglitazone and rosiglitazone.

89 dings indicate that the PPAR-gamma agonists, troglitazone and the J series of prostaglandins, are pot

90 earch on the non-glucose lowering effects of troglitazone and, to a lesser extent, of rosiglitazone a

91 ptor gamma (PPARgamma) ligands (ciglitazone, troglitazone, and 15-deoxy-Delta(12,14) prostaglandin J(

92 gamma agonists [pioglitazone, rosiglitazone, troglitazone, and 15-deoxy-Delta12,14-prostaglandin J2 (

93 show that PPARgamma ligands (rosiglitazone, troglitazone, and 15-deoxy-Delta12,14-prostaglandin J2)

94 ds 15-deoxy-delta(12,14)-prostaglandin J(2), troglitazone, and ciglitazone inhibited 17beta-estradiol

95 tor-activated receptor (PPAR) gamma agonist, troglitazone, and inhibited in the presence of a PPARgam

96 gands (15-deoxy-Delta12,14-prostaglandin J2, troglitazone, and rosiglitazone) in cat corneal fibrobla

97 d exercise), insulin sensitizers (metformin, troglitazone), angiotensin converting enzyme inhibitors

98 Additionally, troglitazone antagonizes rosiglitazone-stimulated PPAR-g

99 Rats were fed troglitazone as a 0.2% food admixture over a 3-week exer

100 regulation provides a molecular basis to use troglitazone as a platform to design AR-ablative agents.

101 chanism provided a molecular basis for using troglitazone as scaffold to develop a novel class of cyc

102 activated receptor gamma (PPARgamma) agonist troglitazone at high doses was able to suppress androgen

103 activated receptor gamma (PPARgamma) ligand (troglitazone) attenuated induction of these genes but en

104 Troglitazone became available in the United States in 19

105 In vivo, treatment with troglitazone before ischemia prevented induction of Egr-

106 Both 15-d-PGJ2 and troglitazone blocked C/EBPbeta transcriptional activity

107 xperienced a 1.7-kg weight gain while taking troglitazone but no other untoward effects.

108 rostaglandin J2) and a PPAR-gamma activator (troglitazone), but not a PPAR-alpha activator (bezafibra

109 dexamethasone-induced insulin resistance by troglitazone, but not in response to troglitazone alone.

110 hanism for the insulin-sensitizing effect of troglitazone, but not metformin, involves enhanced PI 3-

111 5-deoxy-Delta(12,14)-PGJ(2) (15d-PGJ(2)) and troglitazone, but not PPARalpha agonist WY-14643, inhibi

112 ld-type adipocytes with the PPARgamma ligand troglitazone causes accelerated adipocyte differentiatio

113 dence indicates that the apoptotic effect of troglitazone, ciglitazone, and their PPARgamma-inactive

114 ) in MM cells and its agonists 15-d-PGJ2 and troglitazone completely abolished IL-6-inducible MM cell

115 Plasma troglitazone concentration (mean 5 microg/ml) was simila

116 ent and blocked the cytoprotective effect of troglitazone consistent with a role of PPARgamma in medi

117 oncentrations in the diabetic patients after troglitazone correlated with the reductions in fasting p

118 Troglitazone decreased plasma PAI-1 antigen concentratio

119 Treatment with troglitazone delayed or prevented the onset of type 2 di

120 Wnt signaling pathway without blocking their troglitazone-dependent differentiation into lipid-laden

121 We report here that PPAR-gamma activation by troglitazone depends on the experimental setting.

122 ion, we developed a novel PPARgamma-inactive troglitazone derivative, STG28, with high potency in cyc

123 The analysis showed that flutamide, troglitazone, diclofenac, isoniazid, and tamoxifen were

124 Troglitazone did not directly inhibit mTOR kinase activi

125 In contrast, amoxicillin clavulanate and troglitazone did not interfere with MDR3 activity.

126 ring structure forms the non-TZD portion of troglitazone, did not inhibit ACS4, indicating that the

127 ct on gene changes induced by tBH treatment, troglitazone dramatically reduced the number of changes

128 pression, 2 days of incubation of LNCaP with troglitazone dramatically suppressed PSA protein express

129 The troglitazone effect on PI 3-kinase activity was associat

130 T116 cells expressing a wild-type PPARgamma, troglitazone enhanced the binding of PPARgamma to PPAR-r

131 In conclusion, troglitazone enhances fibrinolytic system activity in in

132 Troglitazone exerted stimulatory, inhibitory, or no effe

133 Troglitazone exhibited a mixed type inhibition of ACS4.

134 ic agents, such as etoposide and paclitaxel, troglitazone exhibited a synergistic effect by facilitat

135 activated receptor gamma (PPARgamma) agonist troglitazone facilitated beta-catenin down-regulation.

136 15d-PGJ(2) and troglitazone failed to directly inhibit Cdc2 activity in

137 ta12, 14-prostaglandin J(2) (15d-PGJ(2)) and troglitazone for 24 to 96 hours resulted in a dose-depen

138 Troglitazone further protected against BSO toxicity, whe

139 Protection from diabetes in the troglitazone group 1) was closely related to the degree

140 g ischemia or reperfusion, eight pigs in the troglitazone group died of ventricular fibrillation, com

141 other TZDs; however, the order of efficacy (troglitazone > pioglitazone > rosiglitazone) suggests th

142 Again, troglitazone had no effect per se but blocked the dexame

143 Troglitazone had no effect per se, but it was able to no

144 The first, troglitazone, has been associated with liver failure, oc

145 prostaglandin J2 (15-d-delta 12,14-PGJ2) and troglitazone have been examined.

146 Bromfenac and troglitazone hepatotoxicity as well as various herbal re

147 Although the combination of heregulin and troglitazone (HRG/TGZ) induced both apoptosis and necros

148 lacebo) or intensive (diet modification plus troglitazone) hypoglycemic regimen for three months.

149 These results indicate that troglitazone improves insulin responsiveness in skeletal

150 tic) pigs with the insulin-sensitizing agent troglitazone improves recovery of left ventricular (LV)

151 r-activated receptor (PPAR)-gamma activator, troglitazone, improves recovery of left ventricular (LV)

152 lly, we tested the antifibrotic potential of troglitazone in a cat model of photorefractive keratecto

153 t induction of C/EBPalpha gene expression by troglitazone in C3H10T1/2 cells ectopically expressing P

154 The anti-IGF-I effect of troglitazone in mouse skin keratinocytes was due to, at

155 betes who had completed participation in the Troglitazone In Prevention Of Diabetes (TRIPOD) study.

156 PSA levels, suggesting clinical efficacy of troglitazone in prostate cancer.

157 by thiazolidinedione drugs (pioglitazone and troglitazone) in 3T3-L1 adipocytes.

158 tivated receptor-gamma (PPAR-gamma) agonist, troglitazone, in a manner inhibited by T0070907, a PPAR-

159 t on peripheral glucose utilization, whereas troglitazone increased insulin-stimulated glucose utiliz

160 Troglitazone increased skeletal muscle Irs-1 and phospho

161 In this study, both ciglitazone and troglitazone increased Src activation.

162 eatment of hairless mice with ciglitazone or troglitazone increases loricrin, involucrin, and filaggr

163 Acute treatment with troglitazone increases susceptibility to ventricular fib

164 d the POX promoter activation in response to troglitazone, indicating also the involvement of PPARgam

165 ed the inhibitory effect of PTP inhibitor on troglitazone, indicating that troglitazone uses a STAT3

166 thiazolidinediones (TZDs) rosiglitazone and troglitazone induced G(0)-G(1) cell-cycle arrest and apo

167 Furthermore, troglitazone induced Ser-392 phosphorylation of p53 via

168 Furthermore, TRAIL- and troglitazone-induced apoptosis was preceded by a cleavag

169 ytometry analysis showed that 15d-PGJ(2) and troglitazone-induced cell cycle arrest at the G2/M check

170 lls significantly blocked the 15d-PGJ(2) and troglitazone-induced growth inhibition, G2/M arrest, and

171 -independent mechanisms are involved in the troglitazone-induced POX expression.

172 MIX-deficient cells with a PPARgamma ligand, troglitazone, induces C/EBPalpha expression and rescues

173 either enzyme, whereas the thiazolidinedione troglitazone inhibited 3betaHSDII (K(I) = 25.4 +/- 5.1 m

174 Reporter gene studies showed that troglitazone inhibited androgen activation of the AREs i

175 t suppressing AR expression, suggesting that troglitazone inhibited ARE activation by a mechanism oth

176 d phosphorylation of p70S6K, suggesting that troglitazone inhibited IGF-I and p70S6K signaling throug

177 with troglitazone alone or with a mixture of troglitazone, insulin, dexamethasone, and methylisobutyl

178 Troglitazone is an antidiabetic agent that improves the

179 Troglitazone is one of the thiazolidinedione (TZD) class

180 er cells with TRAIL and the PPARgamma ligand troglitazone leads to a reduction of beta-catenin expres

181 th caspase-dependent anti-neoplastic agents, troglitazone may be a promising drug for use against mal

182 Thus, troglitazone may behave as a partial agonist under certa

183 Therefore, troglitazone may have therapeutic benefit in lipoatrophi

184 preventing or reversing insulin resistance, troglitazone may prove to be a valuable therapeutic agen

185 s suggest that the induction of apoptosis by troglitazone may, at least in part, be mediated by targe

186 REBP-1 overexpression, which is prevented by troglitazone, may play a role in the ectopic lipogenesis

187 activated receptor gamma (PPARgamma) agonist troglitazone mediated the repression of cyclin D1 in MCF

188 thyroid hormone, acts to repress the ligand (troglitazone)-mediated transcriptional activity of PPARg

189 ition, TRbetaPV acted to abolish the ligand (troglitazone)-mediated transcriptional activity of PPARg

190 after 12 weeks of treatment with 400 mg/day troglitazone (n = 13) or placebo (n = 12).

191 sal rates and serum adiponectin levels after troglitazone; no such relationship was seen with metform

192 The inhibitor troglitazone occupies the upper portion of the active-si

193 Inhibition by triacsins and troglitazone of long chain fatty acid incorporation into

194 Our aim was to study the effects of troglitazone on adiponectin levels in lean, obese, and d

195 Pioglitazone was less effective than troglitazone on all parameters tested.

196 inocytes, and that the inhibitory effects of troglitazone on cellular proliferation and cyclin D1 exp

197 ative AMPK reversed the inhibitory effect of troglitazone on IGF-I-induced phosphorylation of p70S6K,

198 t in insulin-resistant states, the effect of troglitazone on lipid and glucose turnover in normal ani

199 of these results, we assessed the effects of troglitazone on monocyte/macrophage homing to atheroscle

200 The action of troglitazone on P450c17 was competitive, but it was main

201 and mutant PPARgamma, there was no effect of troglitazone on POX activation, whereas in HT29 cells, w

202 tor receptor (EGFR) transactivation, whereas troglitazone only weakly activates Erk and does not indu

203 Treatment of PC-3 cells with troglitazone or Delta2-TG led to reduced association of

204 haracterization, subjects were randomized to troglitazone or metformin treatment groups; all subjects

205 days of health plan enrollment before first troglitazone prescription during 4 consecutive periods s

206 I, 0.08 to 0.16; P < 0.001), suggesting that troglitazone promoted oxidation of fat.

207 Troglitazone promotes adipocyte differentiation in vitro

208 Two PPAR-gamma ligands, 15d-PGJ2 and troglitazone, protect RGC-5, an established transformed

209 d in RGC-5 cell death, and both 15d-PGJ2 and troglitazone protected the RGC-5 cells from glutamate cy

210 ory has shown that two TZDs, ciglitazone and troglitazone, rapidly induce calcium-dependent p38 mitog

211 In conclusion, troglitazone reduced hepatic sensitivity to FFAs.

212 ion of thiazolidinediones (rosiglitazone and troglitazone) remarkably inhibited insulin-like growth f

213 .1 and 5.4% in women assigned to placebo and troglitazone, respectively (P < 0.01).

214 Specifically, troglitazone reverses both glucocorticoid-induced insuli

215 The withdrawal of troglitazone (Rezulin) and bromfenac (Duract) a few year

216 Here, we demonstrate that troglitazone (Rezulin), a peroxisome proliferator-activa

217 tenone-induced mitochondrial dysfunction and troglitazone (Rezulin)-induced mitochondrial stress.

218 ctivated receptor gamma (PPARgamma) ligands, troglitazone, rosiglitazone, and pioglitazone, strongly

219 Troglitazone selectively inhibited ABCA1 expression (whi

220 d PGD(2)) or synthetic ligands (BRL49653 and troglitazone), selectively inhibited expression of the c

221 The PPARgamma agonist, troglitazone, sensitizes the cells to IFN-gamma treatmen

222 We show troglitazone shifts metabolic fluxes at concentrations p

223 rthermore, cells treated with 15d-PGJ(2) and troglitazone showed elevated expression of p53 and two p

224 ent with these findings, both 15d-PGJ(2) and troglitazone significantly inhibited the G2/M cyclin-dep

225 Topical application of troglitazone significantly reduced alpha-smooth muscle a

226 strate that PPARgamma agonists 15-d-PGJ2 and troglitazone significantly suppress cell-cell adhesive e

227 protein, and marked reductions in basal and troglitazone-stimulated expression of the genes encoding

228 ma by exposure of Swiss mouse fibroblasts to troglitazone stimulates the degradation of beta-catenin,

229 th previous data showing that triacsin C and troglitazone strongly inhibit triacylglycerol synthesis

230 gand clofibrate but not the PPARgamma ligand troglitazone, suggesting the involvement of PPARalpha si

231 Troglitazone suppressed cyclin D1 expression at multiple

232 Troglitazone (TGZ) and 15-deoxy-Delta(12,14)-prostagland

233 Troglitazone (TGZ) is a peroxisome proliferator-activate

234 Troglitazone (TGZ), a member of the thiazolidinedione cl

235 he metabolism of the drugs diclofenac (DCF), troglitazone (TGZ), and raloxifene, for which we observe

236 ctivated receptor-gamma (PPARgamma) agonist, troglitazone, that facilitates caspase signaling in huma

237 Troglitazone, the first in the thiazolidinedione class o

238 Soon after initial marketing in March 1997, troglitazone, the first thiazolidinedione antidiabetic a

239 glucose disposal rate was greater following troglitazone therapy (+44%) compared with metformin trea

240 In combination, exercise and troglitazone therapy (n = 6) produced significant increm

241 In conclusion, 1) exercise and troglitazone therapy each improved insulin action in the

242 Troglitazone therapy improved metabolic control and incr

243 Troglitazone therapy lowered myocardial TG and ceramide

244 treated fa/fa rats was blocked by 6 weeks of troglitazone therapy, and the diabetic phenotype was pre

245 ents with diabetes who completed 6 months of troglitazone therapy, hemoglobin A1c levels decreased by

246 In addition, as the ability of troglitazone to induce adipocyte differentiation is also

247 major concern is that the concentration for troglitazone to mediate antitumor effects is severalfold

248 the question of whether the ability of oral troglitazone to reduce PSA levels in prostate cancer pat

249 As a consequence, the ability of troglitazone to target these F-box proteins provides a m

250 We conclude that the ability of troglitazone to upregulate adipocyte glucose transport,

251 the potential for severe hepatic injury (eg, troglitazone, tolcapone).

252 ake after reperfusion was 7 times greater in troglitazone-treated pigs than in untreated pigs, sugges

253 c region recovered to 44+/-6% of baseline in troglitazone-treated pigs versus 18+/-6% of baseline in

254 Troglitazone-treated subjects displayed a tendency towar

255 stimulated Akt activity also increased after troglitazone treatment (from 32 +/- 8 to 107 +/- 32% sti

256 ctivity was augmented nearly threefold after troglitazone treatment (from 67 +/- 22% stimulation over

257 tective genotype at CDKN2A/B after 1 year of troglitazone treatment (P = 0.01) and possibly lifestyle

258 abdominal adipocytes was increased following troglitazone treatment and unchanged after metformin.

259 ncreased eightfold during the 10th months of troglitazone treatment but normalized 3 months after dis

260 Rosiglitazone or troglitazone treatment did not reduce glucose or insulin

261 Before ischemia, acute troglitazone treatment had no effect on LV function, ele

262 In nondiabetic pigs, chronic troglitazone treatment improves recovery of LV systolic

263 beta-cell function that had occurred during troglitazone treatment in the TRIPOD study.

264 Troglitazone treatment increased serum adiponectin level

265 Troglitazone treatment of type 2 diabetic patients dimin

266 Troglitazone treatment resulted in a 35 +/- 9% improveme

267 from baseline in insulin sensitivity during troglitazone treatment was accounted for by lowered plas

268 After troglitazone treatment, GLUT4 protein expression was inc

269 After troglitazone treatment, nocturnal palmitate R(a) did not

270 After troglitazone treatment, rates of insulin-stimulated whol

271 ell with improved insulin sensitivity during troglitazone treatment, so that the disposition index fo

272 ease from adipocytes was also augmented with troglitazone treatment.

273 (418 +/- 161%, P < 0.05) was elevated after troglitazone treatment.

274 ally or peripherally, both before and during troglitazone treatment.

275 Two PPAR-gamma ligands, troglitazone (TRO) and rosiglitazone (RSG; 0.1-20 microM

276 eviously reported that the PPARgamma agonist troglitazone (TRO) inhibits proliferation and induces ap

277 The TZD troglitazone (TRO) inhibits vascular smooth muscle cell

278 some proliferator-activated receptor agonist troglitazone (TRO) was used for treatment of non-insulin

279 ent of lung adenocarcinoma cells (A549) with troglitazone (Tro), a PPAR-gamma ligand, enhanced PPAR-g

280 monstrate that the TZDs rosiglitazone (RSG), troglitazone (TRO), and a novel non-TZD partial PPARgamm

281 PPARgamma ligands troglitazone (TRO, 10 microm) and rosiglitazone (RSG, 10

282 exposure to BDE-47 or the antidiabetic drug troglitazone (TROG).

283 Addition of PPARgamma ligand troglitazone (TZD) activated PPARgamma2 in proliferating

284 atorial treatment with the thiazolidinedione troglitazone (TZD) and TNF-related apoptosis-inducing li

285 Our earlier studies have shown that troglitazone (TZD)-mediated activation of PPARgamma2 in

286 P inhibitor on troglitazone, indicating that troglitazone uses a STAT3 inactivation mechanism that ma

287 ts of lifestyle intervention, metformin, and troglitazone versus placebo.

288 ational differences in the receptor bound to troglitazone versus rosiglitazone.

289 -activated receptor gamma (PPARgamma) ligand troglitazone was found to activate the POX promoter in c

290 sal rates by 20% (P < 0.05); the response to troglitazone was greater (44% increase, P < 0.01 vs. bas

291 A total of 600 mg troglitazone was then given orally each day for 3 weeks

292 on by PPAR gamma-specific ligands (BRL49653, troglitazone) was enhanced in cyclin D1(-/-) fibroblasts

293 gulated by tBH and selectively normalized by troglitazone were identified.

294 oxy-D(12,14)-prostaglandin J2 (15d-PGJ2) and troglitazone were used.

295 nsity lipoprotein, docosahexaenoic acid, and troglitazone, whereas activity of a luciferase gene plac

296 We tested the hypothesis that troglitazone, which improves insulin sensitivity and low

297 ator-activated receptor (PPAR) gamma agonist troglitazone, which is associated with cytoplasmic lipid

298 ty was obtained in HCT116 cells treated with troglitazone with a concomitant increase in the producti

299 Three nonresponders to troglitazone with respect to effects on insulin sensitiv

300 d to STG28, a PPARgamma-inactive analogue of troglitazone with substantially higher potency in AR rep